Clinical Trials

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

The purpose of this study is to obtain clinical specimens, supporting clinical information, and laboratory testing results from patients from the upper Midwestern United States with early (acute) LD or with evidence of Lyme arthritis (LA). The specimens and well-characterized patient data will become part of a national repository of serum samples maintained by the CDC National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Disease. The samples will be available for external requestors for use in developing and evaluating improved serologic tests for LD.

Eagle River Center

500 COMMERCE LOOP

EAGLE RIVER, WI 54521

Greenwood Center

102 W CANNERY STREET

GREENWOOD, WI 54437

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Lake Hallie Center

12961 27TH AVE

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MMC - Eau Claire

2116 Craig Rd

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Neillsville

216 Sunset Place

Neillsville, Wisconsin 54456

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

Stratford Center

101 WISCONSIN AVE

STRATFORD, WI 54484

The Heartland Study is a prospective, observational study that will enroll up to 2,600 pregnant participants across the Heartland States in the U.S. The objective of the Heartland Study is to address major knowledge gaps concerning the health effects of herbicides on maternal and infant health. The study is being conducted to evaluate the associations between environmental exposures to herbicides during and after pregnancy and reproductive health outcomes. The study is measuring multiple biomarkers of herbicide exposure among pregnant Midwesterners and their partners to evaluate associations with pregnancy and childbirth outcomes, epigenetic biomarkers of exposure, and child development.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This is a Prospective Observational Cohort Study, designed to better characterize patients with cancer cachexia (CC) by prospectively evaluating weight, muscle mass, fat mass, eating and appetite, physical function, symptoms, and associated medical and biopsychosocial factors. CC was defined by an international consensus panel as a “multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment1.” CC has been associated with reduced physical performance, impaired quality of life and poorer survival. Unfortunately, there currently are no Food and Drug Administration (FDA)-approved treatment for CC. Therefore, therapeutic development for CC is an urgent unmet need. The diagnostic criteria for CC as defined by the international consensus are as follows: a) greater than 5% weight loss in the previous 6 months or b) greater than 2% weight loss with either low Body Mass Index (BMI) or skeletal muscle depletion. A key criticism of the diagnostic criteria is that it is too broad and simplistic for a complex, multifactorial disease process and that it relies too heavily on weight, which is subject to change from a myriad of conditions. The aim of this study will be to develop new diagnostic criteria for CC subtypes so that pathophysiologic drivers of CC can be isolated in individuals and, ultimately, more tailored therapies can be developed.

MMC - Dickinson

1721 S Stephenson Ave

Iron Mountain, MI 49801

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W Stout St

Rice Lake, WI 54868

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

The primary objective is to confirm the safety and effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (“VBX Device” or also referred to as “VBX Stent Graft”) when used in covered endovascular reconstruction of the aortic bifurcation (CERAB) to treat AIOD.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Velos_Test_01042023

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This is a prospective cohort study that examines the impact of myopenia on chemotherapy toxicity in overall survival (OS) in older adults with newly diagnosed metastatic colorectal cancer (CRC) receiving 5-Fluouracil (5FU)systemic chemotherapy. The study also explores the mediating influence of genetic variation in the association between myopenia and chemotherapy toxicity.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - Dickinson

1721 S Stephenson Ave

Iron Mountain, MI 49801

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476